Everest Medicines Limited (HKG:1952)
55.75
+0.80 (1.46%)
Sep 29, 2025, 4:08 PM HKT
Everest Medicines Revenue
Everest Medicines had revenue of 446.12M CNY in the half year ending June 30, 2025, with 4,915.44% growth. This brings the company's revenue in the last twelve months to 851.28M, up 103.39% year-over-year. In the year 2024, Everest Medicines had annual revenue of 706.68M with 461.16% growth.
Revenue (ttm)
851.28M CNY
Revenue Growth
+103.39%
P/S Ratio
20.81
Revenue / Employee
1.28M CNY
Employees
665
Market Cap
19.41B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 706.68M | 580.75M | 461.16% |
Dec 31, 2023 | 125.93M | 113.14M | 884.46% |
Dec 31, 2022 | 12.79M | 12.74M | 23,588.89% |
Dec 31, 2021 | 54.00K | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BeOne Medicines AG | 35.81B |
JD Health International | 71.34B |
Hansoh Pharmaceutical Group Company | 14.45B |
Innovent Biologics | 12.52B |
WuXi Biologics | 21.98B |
Sino Biopharmaceutical | 33.49B |
Akeso | 2.75B |
Sichuan Kelun-Biotech Biopharmaceutical | 1.64B |
Everest Medicines News
- 6 months ago - AI-powered Cancer Vaccine In The Works - Benzinga
- 1 year ago - Kezar Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update - Benzinga